SecBot SecBot
8-K ·Filed Nov 10, 2026

PMVP

PMV Pharmaceuticals, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed11d 23h ago SEC0001193125-26-454467
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key catalyst is the late-breaking oral presentation of PYNNACLE Phase 2 data at ENA 2026 and the Q1 2027 NDA submission for accelerated approval. Monitor for any efficacy or safety signals from the full dataset that could affect the NDA's likelihood of acceptance.

DirectionNeutral
Confidencehigh
Horizonmonths

rezatapopt

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2 (pivotal)
Time to market
NDA submission planned for Q1 2027 under accelerated approval pathway. If accepted and approved under standard review timelines, potential FDA decision could come in late 2027 or early 2028.
Next catalyst
NDA filing · Q1 2027

What to watchThe next catalyst is the late-breaking oral presentation of updated PYNNACLE Phase 2 data at ENA 2026 on November 20, 2026, roughly 9 days away. Positive data could reinforce the NDA submission narrative and support the stock, while disappointing results (weaker efficacy or safety signals) could undermine the accelerated approval path. The NDA submission itself, planned for Q1 2027, is the next major binary event after ENA.

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+5
Entry
$1.22
T+0 close · Nov 10, 2026 · via day close
Latest settled
0.00%
T+5 · $1.22
Vs SPY
+2.33%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 10 $1.22entry
  2. T+1 · 11d ago +3.28%α +1.96% · $1.26
  3. T+5 · 5d ago 0.00%α +2.33% · $1.22
  4. T+8 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PMV Pharma reported Q3 2026 net loss of $34.4M, wider than the $21.1M loss in Q3 2025, driven by a $12.8M non-cash warrant liability charge from the August 2026 $50M public offering. The company highlighted an ORR of 46% in the pivotal Phase 2 PYNNACLE trial for rezatapopt in TP53 Y220C ovarian cancer, with an NDA submission planned for Q1 2027. Cash of $108.5M extends runway into Q1 2028.

Key Financial Metrics

EPS
−$0.52

Key Facts

  • Net loss for Q3 2026 was $34.4M vs $21.1M in Q3 2025, primarily due to a $12.8M non-cash loss from change in fair value of warrant liability and $2.3M offering costs allocated to the warrant liability.
  • Cash, cash equivalents, and marketable securities were $108.5M as of September 30, 2026, providing expected cash runway into Q1 2028.
  • Closed an oversubscribed $50M public offering of securities in August 2026.
  • Pivotal Phase 2 PYNNACLE trial data for rezatapopt showed an ORR of 46% (35/76 patients) in platinum-resistant/refractory ovarian cancer, with median time to response of 1.3 months and median duration of response of 10.0 months.
  • NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer planned for Q1 2027.
  • R&D expenses decreased to $16.1M from $18.2M year-over-year.
  • Appointed Matt Eckler, Ph.D., to Board of Directors and Philip Herman as Chief Commercial Officer.

Financial Impact

Net loss widened by $13.3M YoY to $34.4M, but operating loss improved to $20.1M from $22.5M. Cash position increased to $108.5M from $79.4M at June 30, 2026, following the $50M offering.

net losscash positionoperating expenses

Risk Factors

  • Net loss increased significantly due to non-cash warrant liability charges from the August 2026 offering.
  • The company is pre-revenue and depends on successful NDA submission and FDA approval of rezatapopt.
  • Clinical trial results may not support accelerated approval; the NDA is based on a single-arm Phase 2 study.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-454467
Document: pmvp-20261110.htm0001193125-26-454467
Document: 0001193125-26-454467-index-headers.html0001193125-26-454467
Document: 0001193125-26-454467-index.html0001193125-26-454467
Document: 0001193125-26-454467.txt0001193125-26-454467
8-K Data (Synthetic)0001193125-26-454467

Track record

14 reports on PMVP

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +29.46% at T+20 after the Aug 31, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 20, 20261d ago Press Release Bullish 7/10 Entry $1.20 Now $0.8760 −27.00% settles Dec 21
  2. Nov 16, 20265d ago SC 13G/A Neutral 3/10 Entry $1.22 Now $0.8760 −28.20% settles Dec 16
  3. Nov 10, 202611d ago 8-K Neutral 5/10 Viewing Entry $1.22 Now $0.8760 −28.20% settles Dec 9
  4. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $1.78 to $1.31 Now $0.8760 −50.79% ▼ −26.40% −23.94% vs SPY
  5. Aug 31, 202611w ago Press Release Bearish 8/10 Entry $1.29 to $1.67 Now $0.8760 +32.09% ▼ −29.46% −29.14% vs SPY
  6. Aug 31, 202611w ago 8-K Bullish 7/10 Entry $1.29 to $1.67 Now $0.8760 −32.09% ▲ +29.46% +29.14% vs SPY
  7. Aug 31, 202611w ago Press Release Bearish 6/10 Entry $1.29 to $1.67 Now $0.8760 +32.09% ▼ −29.46% −29.14% vs SPY
  8. Aug 31, 202611w ago Press Release Bullish 8/10 Entry $1.29 to $1.67 Now $0.8760 −32.09% ▲ +29.46% +29.14% vs SPY
  9. Aug 14, 202614w ago 8-K Neutral 5/10 No price data
  10. Aug 14, 202614w ago Press Release Bullish 6/10 Entry $1.26 to $1.46 Now $0.8760 −30.48% ▲ +15.87% +17.86% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Mon (26h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026